Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
NAFDAC is intensifying regulatory oversight in the pharmaceutical and healthcare sectors through new training mandates, product blacklisting, and watchlist alerts, while also expanding its pharmacist reserve corps. For Nigerian SMBs in pharma, healthcare, and related distribution, this means stricter compliance requirements and heightened scrutiny of imported and marketed products. Businesses should verify product authenticity, ensure staff are trained on clinical trial regulations, and monitor NAFDAC notices to avoid regulatory penalties.
Pharmaceuticals
Healthcare
Importation and Distribution
Clinical Trials
Food and Drug Regulation
NAFDAC and NHREC Announce New Dates for Mandatory Stakeholders Training on Clinical Trial Regulations in Nigeria
NAFDAC
NAFDAC and NHREC have rescheduled mandatory training on clinical trial regulations for stakeholders in Nigeria.
SMBs involved in clinical trials or pharmaceutical research must ensure their staff attend this training to remain compliant with regulatory requirements.
Public Notice on Blacklisting Ayrtons Saunders Ltd, UK
NAFDAC
NAFDAC has blacklisted Ayrtons Saunders Ltd, UK, and its products, warning importers, distributors, and healthcare institutions against dealing with them.
SMBs importing or distributing products from this company must immediately cease and verify their supply chains to avoid regulatory sanctions.
Public Alert No. 043/2026-NAFDAC Places Products Marketed by Mofus Nigeria Ltd on Watchlist Pending Regulatory Investigation
NAFDAC
NAFDAC has placed products marketed by Mofus Nigeria Ltd on a watchlist pending investigation, alerting healthcare professionals and distributors.
SMBs in pharmaceutical retail or distribution should avoid stocking or selling these products until the investigation concludes.
Inauguration Ceremony of the NAFDAC Pharmacist Reserve Group
NAFDAC
NAFDAC inaugurated a Pharmacist Reserve Group comprising 600 pharmacists to provide voluntary service.
This may enhance regulatory capacity and support for SMBs in the pharmaceutical sector, potentially improving compliance and inspection processes.
Address by Prof. Mojisola Christianah Adeyeye at the 49th Annual International Conference of the Chemical Society of Nigeria
NAFDAC
The NAFDAC DG addressed innovations in medicinal and pharmaceutical chemistry for affordable healthcare delivery.
SMBs in pharmaceutical manufacturing and chemistry should note the emphasis on innovation and affordability, which may influence future regulatory trends.
Increased regulatory scrutiny on imported pharmaceutical products and supply chains.
Mandatory training requirements for clinical trial stakeholders may affect SMBs involved in research.
Watchlist and blacklisting actions signal need for rigorous supplier verification.
NAFDAC's expanded pharmacist reserve may lead to more frequent inspections and support.
Focus on affordable healthcare innovation could open opportunities for compliant SMBs.
1
Verify all pharmaceutical products against NAFDAC's blacklist and watchlist before importation or distribution.
2
Register for and attend the mandatory clinical trial regulations training if involved in clinical trials.
3
Conduct immediate supply chain audits to ensure no products from blacklisted companies are in stock.
4
Stay updated with NAFDAC public alerts and notices through their official website.
5
Ensure all staff involved in pharmaceutical handling are aware of regulatory changes and compliance requirements.